← All trials
NCT04975997
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 12, 2021
- Primary completion
- May 17, 2024
- Completion date
- Dec 29, 2029
- First posted
- Jul 26, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 730
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CelgeneLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.